References
- Vedsted P, Olesen F. Early diagnosis of cancer: The role of general practice. Scand J Prim Health Care 2009;27:193–4.
- Getz L, Brodersen J. Informed participation in cancer screening: The facts are changing, and GPs are going to feel it. Scand J Prim Health Care 2010;28:1–3.
- Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: The global picture. Eur J Cancer 2001;37(Suppl 8): S4–66.
- Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the US Preventive Services Task Force. Ann Intern Med 2008;149:192–9.
- Stark JR, Mucci L, Rothman KJ, Adami HO. Screening for prostate cancer remains controversial. BMJ 2009;339:b3601.
- Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007;167:2497–502.
- Kvåle R, Auvinen A, Adami HO, . Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881–7.
- Draisma G, Etzioni R, Tsodikov A, . Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 2009;101:374–83.
- Andriole GL, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–19.
- Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V, . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360: 1320–8.
- Djulbegovic M, Beyth RJ, Neuberger MM . Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
- Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539.